Supported by Thermo Fisher Scientific
With the overlap of flu season and the SARS-CoV-2 outbreak, it is vital that clinical and public health laboratories have access to a single test that can detect RNA from multiple respiratory viruses. As a world leader in COVID-19 testing, Thermo Fisher Scientific has worked rapidly to develop a new multiplex real-time PCR diagnostic kit for the simultaneous detection of SARS-CoV-2, influenza A, and influenza B, which all present with similar clinical symptoms. This highly accurate real-time PCR test is Emergency Use Authorized, allowing you to expand your respiratory sample testing menu while maintaining low operational costs. Join this talk to learn more about the TaqPath COVID-19, Flu A, Flu B Combo Kit and see performance data.
Michael Schumaker Director, Research and Development, Genetic Testing Solutions Thermo Fisher Scientific